Related references
Note: Only part of the references are listed.Efficacy and tolerability of repeated cycles of a once-weekly regimen of bortezomib in lupus
Luca Quartuccio et al.
RHEUMATOLOGY (2014)
The Emerging Role of the Ubiquitin Proteasome in Pulmonary Biology and Disease
Nathaniel M. Weathington et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2013)
High cereblon expression is associated with better survival in patients with newly diagnosed multiple myeloma treated with thalidomide maintenance
Annemiek Broyl et al.
BLOOD (2013)
Identification of repurposed small molecule drugs for chordoma therapy
Menghang Xia et al.
CANCER BIOLOGY & THERAPY (2013)
Nanoparticles Engineered with Rituximab and Loaded with Nutlin-3 Show Promising Therapeutic Activity in B-Leukemic Xenografts
Rebecca Voltan et al.
CLINICAL CANCER RESEARCH (2013)
Pomalidomide: First Global Approval
Shelley Elkinson et al.
DRUGS (2013)
Over-Expression of Deubiquitinating Enzyme USP14 in Lung Adenocarcinoma Promotes Proliferation through the Accumulation of β-Catenin
Ning Wu et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2013)
Targeting F Box Protein Fbxo3 To Control Cytokine-Driven Inflammation
Rama K. Mallampalli et al.
JOURNAL OF IMMUNOLOGY (2013)
The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects
M. A. Hurchla et al.
LEUKEMIA (2013)
A combinatorial F box protein directed pathway controls TRAF adaptor stability to regulate inflammation
Bill B. Chen et al.
NATURE IMMUNOLOGY (2013)
Rapid Identification of Antifungal Compounds against Exserohilum rostratum Using High Throughput Drug Repurposing Screens
Wei Sun et al.
PLOS ONE (2013)
Linear ubiquitination: a newly discovered regulator of cell signalling
Eva Rieser et al.
TRENDS IN BIOCHEMICAL SCIENCES (2013)
Skp-cullin-F box E3 ligase component FBXL2 ubiquitinates Aurora B to inhibit tumorigenesis
B. B. Chen et al.
CELL DEATH & DISEASE (2013)
REFRACTORY SLE PATIENTS RESPOND TO THE PROTEASOME INHIBITOR BORTEZOMIB
F. Hiepe et al.
ANNALS OF THE RHEUMATIC DISEASES (2012)
Ubiquitin and Membrane Protein Turnover: From Cradle to Grave
Jason A. MacGurn et al.
ANNUAL REVIEW OF BIOCHEMISTRY, VOL 81 (2012)
An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma
Ravi Vij et al.
BLOOD (2012)
A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma
Andrzej J. Jakubowiak et al.
BLOOD (2012)
Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma
Michele Cavo et al.
BLOOD (2012)
Design and rationale of FOCUS (PX-171-011): A randomized, open-label, phase 3 study of carfilzomib versus best supportive care regimen in patients with relapsed and refractory multiple myeloma (R/R MM)
Roman Hajek et al.
BMC CANCER (2012)
An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib
Ravi Vij et al.
BRITISH JOURNAL OF HAEMATOLOGY (2012)
A Small Molecule Inhibitor of Ubiquitin-Specific Protease-7 Induces Apoptosis in Multiple Myeloma Cells and Overcomes Bortezomib Resistance
Dharminder Chauhan et al.
CANCER CELL (2012)
P53 Mdm2 Inhibitors
Kareem Khoury et al.
CURRENT PHARMACEUTICAL DESIGN (2012)
Governance of Endocytic Trafficking and Signaling by Reversible Ubiquitylation
Michael J. Clague et al.
DEVELOPMENTAL CELL (2012)
Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination
Michael Millward et al.
INVESTIGATIONAL NEW DRUGS (2012)
Targeting the von Hippel-Lindau E3 Ubiquitin Ligase Using Small Molecules To Disrupt the VHL/HIF-1α Interaction
Dennis L. Buckley et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2012)
Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide
A. Lopez-Girona et al.
LEUKEMIA (2012)
F-box protein FBXL2 exerts human lung tumor suppressor-like activity by ubiquitin-mediated degradation of cyclin D3 resulting in cell cycle arrest
B. B. Chen et al.
ONCOGENE (2012)
Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide
Yuan Xiao Zhu et al.
BLOOD (2011)
Preclinical assessment of JNJ-26854165 (Serdemetan1), a novel tryptamine compound with radiosensitizing activity in vitro and in tumor xenografts
Cyrus Chargari et al.
CANCER LETTERS (2011)
An Allosteric Inhibitor of the Human Cdc34 Ubiquitin-Conjugating Enzyme
Derek F. Ceccarelli et al.
CELL (2011)
Activity-Based Chemical Proteomics Accelerates Inhibitor Development for Deubiquitylating Enzymes
Mikael Altun et al.
CHEMISTRY & BIOLOGY (2011)
A Phase I First-in-Human Pharmacokinetic and Pharmacodynamic Study of Serdemetan in Patients with Advanced Solid Tumors
Josep Tabernero et al.
CLINICAL CANCER RESEARCH (2011)
A Small-Molecule Inhibitor of MDMX Activates p53 and Induces Apoptosis
Hongbo Wang et al.
MOLECULAR CANCER THERAPEUTICS (2011)
Mechanism of Action of Proteasome Inhibitors and Deacetylase Inhibitors and the Biological Basis of Synergy in Multiple Myeloma
Teru Hideshima et al.
MOLECULAR CANCER THERAPEUTICS (2011)
Inhibition of proteasome deubiquitinating activity as a new cancer therapy
Padraig D'Arcy et al.
NATURE MEDICINE (2011)
MEDICAL PROGRESS Multiple Myeloma
Antonio Palumbo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
The NCGC Pharmaceutical Collection: A Comprehensive Resource of Clinically Approved Drugs Enabling Repurposing and Chemical Genomics
Ruili Huang et al.
SCIENCE TRANSLATIONAL MEDICINE (2011)
Human ITCH E3 Ubiquitin Ligase Deficiency Causes Syndromic Multisystem Autoimmune Disease
Naomi J. Lohr et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2010)
Pharmacologic Inhibition of the Anaphase-Promoting Complex Induces A Spindle Checkpoint-Dependent Mitotic Arrest in the Absence of Spindle Damage
Xing Zeng et al.
CANCER CELL (2010)
Deubiquitinase Inhibition by Small-Molecule WP1130 Triggers Aggresome Formation and Tumor Cell Apoptosis
Vaibhav Kapuria et al.
CANCER RESEARCH (2010)
CYLD: a tumor suppressor deubiquitinase regulating NF-kappa B activation and diverse biological processes
S-C Sun
CELL DEATH AND DIFFERENTIATION (2010)
Sent to Destroy The Ubiquitin Proteasome System Regulates Cell Signaling and Protein Quality Control in Cardiovascular Development and Disease
Monte S. Willis et al.
CIRCULATION RESEARCH (2010)
Enhancement of proteasome activity by a small-molecule inhibitor of USP14
Byung-Hoon Lee et al.
NATURE (2010)
An allosteric inhibitor of substrate recognition by the SCFCdc4 ubiquitin ligase
Stephen Orlicky et al.
NATURE BIOTECHNOLOGY (2010)
Chemical genetics screen for enhancers of rapamycin identifies a specific inhibitor of an SCF family E3 ubiquitin ligase
Mariam Aghajan et al.
NATURE BIOTECHNOLOGY (2010)
Identification of a Primary Target of Thalidomide Teratogenicity
Takumi Ito et al.
SCIENCE (2010)
An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer
Teresa A. Soucy et al.
NATURE (2009)
Breaking the chains: structure and function of the deubiquitinases
David Komander et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2009)
Thalidomide for treatment of multiple myeloma: 10 years later
Antonio Palumbo et al.
BLOOD (2008)
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma
Jesus F. San Miguel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Improved survival in multiple myeloma and the impact of novel therapies
Shaji K. Kumar et al.
BLOOD (2008)
Identification of new compounds that trigger apoptosome-independent caspase activation and apoptosis
Emanuela Aleo et al.
CANCER RESEARCH (2006)
Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib
Paul G. Richardson et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Crystal structure of the boronic acid-based proteasome inhibitor bortezomib in complex with the yeast 20S proteasome
M Groll et al.
STRUCTURE (2006)
A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib
D Chauhan et al.
CANCER CELL (2005)
Timeline - The evolution of thalidomide and its IMiD derivatives as anticancer agents
JB Bartlett et al.
NATURE REVIEWS CANCER (2004)
Proteasomes and their kin: Proteases in the machine age
CM Pickart et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2004)
In vivo activation of the p53 pathway by small-molecule antagonists of MDM2
LT Vassilev et al.
SCIENCE (2004)
The SCF ubiquitin ligase: Insights into a molecular machine
T Cardozo et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2004)
The ubiquitin proteasome system in neurodegenerative diseases: Sometimes the chicken, sometimes the egg
A Ciechanover et al.
NEURON (2003)
Discovery of inhibitors that elucidate the role of UCH-L1 activity in the H1299 lung cancer cell line
YC Liu et al.
CHEMISTRY & BIOLOGY (2003)
Loss of the cylindromatosis tumour suppressor inhibits apoptosis by activating NF-κB
TR Brummelkamp et al.
NATURE (2003)
The tumour suppressor CYLD negatively regulates NF-κB signalling by deubiquitination
A Kovalenko et al.
NATURE (2003)
CYLD is a deubiquitinating enzyme that negatively regulates NF-κB activation by TNFR family members
E Trompouki et al.
NATURE (2003)
A phase 2 study of bortezomib in relapsed, refractory myeloma
PG Richardson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Share Paper
